Area of research
Biotechnology · Biomaterials
Research interest
Research focused on Cancer research and Cetuximab, with related work in Erlotinib, Carboplatin, Histone acetyltransferase. Notable publications include 'Histone acetyltransferase inhibitors block neuroblastoma cell growth in vivo', 'Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma', and 'QSEA—modelling of genome-wide DNA methylation from sequencing enrichment experiments'.
GIPC1 regulates MACC1-driven metastasis
Patient-derived xenograft (PDX) models of colorectal carcinoma (CRC) as a platform for chemosensitivity and biomarker analysis in personalized medicine
Mutation-specific effects of NRAS oncogenes in colorectal cancer cells
Loss-of-function uORF mutations in human malignancies
Epigenomic profiling of non-small cell lung cancer xenografts uncover LRP12 DNA methylation as predictive biomarker for carboplatin resistance
Basal subtype is predictive for response to cetuximab treatment in patient-derived xenografts of squamous cell head and neck cancer
QSEA—modelling of genome-wide DNA methylation from sequencing enrichment experiments
Abstract 2412: Reconstructing intratumor heterogeneity: lessons from therapeutic intervention in patient-specific models
Histone acetyltransferase inhibitors block neuroblastoma cell growth in vivo
SPON2, a newly identified target gene of MACC1, drives colorectal cancer metastasis in mice and is prognostic for colorectal cancer patient survival
Essential role of IRF4 and MYC signaling for survival of anaplastic large cell lymphoma
Activation of AMP-activated protein kinase sensitizes lung cancer cells and H1299 xenografts to erlotinib
Testing of SNS-032 in a Panel of Human Neuroblastoma Cell Lines with Acquired Resistance to a Broad Range of Drugs